Analysts Set Mesoblast Limited (NASDAQ:MESO) Price Target at $10.13

Mesoblast Limited (NASDAQ:MESO – Get Rating) has been assigned an average rating of “Hold” from the six brokerages that are currently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $10.13.

Several equities research analysts have commented on the company. StockNews.com assumed coverage on Mesoblast in a report on Thursday, May 18th. They issued a “sell” rating on the stock. William Blair assumed coverage on Mesoblast in a report on Thursday, March 9th. They issued an “outperform” rating and a $8.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $23.00 target price on shares of Mesoblast in a report on Wednesday, February 1st. Finally, Chardan Capital reissued a “sell” rating and issued a $2.50 target price on shares of Mesoblast in a report on Wednesday, March 1st.

Mesoblast Trading Down 1.1 %

NASDAQ MESO opened at $3.45 on Tuesday. The company has a quick ratio of 1.43, a current ratio of 1.43 and a debt-to-equity ratio of 0.19. Mesoblast has a twelve month low of $2.14 and a twelve month high of $4.35. The firm has a market capitalization of $561.80 million, a PE ratio of -5.56 and a beta of 3.27. The stock’s 50 day moving average is $3.37 and its 200 day moving average is $3.30.

Mesoblast (NASDAQ:MESO – Get Rating) last released its quarterly earnings results on Monday, February 27th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Mesoblast had a negative net margin of 1,068.42% and a negative return on equity of 16.52%. The firm had revenue of $2.13 million for the quarter, compared to the consensus estimate of $1.50 million. Research analysts forecast that Mesoblast will post -0.64 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of MESO. State Street Corp purchased a new position in shares of Mesoblast in the first quarter worth $757,000. Ronit Capital LLP purchased a new position in shares of Mesoblast in the third quarter worth $382,000. BlackRock Inc. raised its stake in shares of Mesoblast by 20.8% in the first quarter. BlackRock Inc. now owns 864,638 shares of the company’s stock worth $3,649,000 after purchasing an additional 149,023 shares during the last quarter. Millennium Management LLC purchased a new position in shares of Mesoblast in the fourth quarter worth $344,000. Finally, Jane Street Group LLC purchased a new stake in Mesoblast during the fourth quarter valued at $187,000. Hedge funds and other institutional investors own 2.60% of the company’s stock.

Mesoblast Company Profile

(Get Rating)

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases.